Showing results (121-130 of 186) with videos related to
Sort By:
Pageof 19
The American Journal of Cardiology|March 12, 1999
Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study InvestigatorsT P Bell, V DeQuattro, K C Lasseter, et al.Clinical Therapeutics|July 15, 1998
Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension. Enalapril-Felodipine ER Factorial Study GroupA H Gradman, N R Cutler, P J Davis, et al.Circulation|February 1, 1988
Inducible sustained ventricular tachycardia 4 years after experimental canine myocardial infarction: electrophysiologic and anatomic comparisons with early healed infarctsR F Hanich, C D de Langen, A H Kadish, et al.The American Journal of Cardiology|May 1, 1978
Fascicular conduction distrubances after coronary bypass surgeryS M Zeldis, J Morganroth, L N Horowitz, et al.The American Journal of Cardiology|October 30, 1998
Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study InvestigatorsM Reif, W B White, T C Fagan, et al.Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialSalim Yusuf, Marc A Pfeffer, Karl Swedberg, et al.Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialChristopher B Granger, John J V McMurray, Salim Yusuf, et al.Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialJohn J V McMurray, Jan Ostergren, Karl Swedberg, et al.Journal of the American College of Cardiology|October 24, 2002
The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective studyAgha W Haider, Peter W F Wilson, Martin G Larson, et al.Journal of the American College of Cardiology|May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programLars G Olsson, Karl Swedberg, Anique Ducharme, et al.Pageof 19